MARKET

AGEN

AGEN

Agenus
NASDAQ
5.99
-1.31
-17.95%
After Hours: 6.05 +0.06 +1.00% 19:58 07/19 EDT
OPEN
7.00
PREV CLOSE
7.30
HIGH
7.29
LOW
5.73
VOLUME
4.10M
TURNOVER
0
52 WEEK HIGH
38.60
52 WEEK LOW
4.775
MARKET CAP
125.79M
P/E (TTM)
-0.4725
1D
5D
1M
3M
1Y
5Y
1D
Agenus Cut to Hold From Buy by Jefferies
Dow Jones · 2d ago
Agenus Price Target Raised to $7.00/Share From $3.00 by Jefferies
Dow Jones · 2d ago
Jefferies Downgrades Agenus to Hold, Raises Price Target to $7
Benzinga · 2d ago
Agenus Faces Regulatory and Financial Challenges: Analyst Downgrades Stock Pending Trial Clarity
Agenus Inc. Announced the results of its end-of-Phase 2 meeting with the FDA to advance its immunotherapy combination. The FDA discouraged the accelerated approval pathway. William Blair has downgraded Agenus stock to Market Perform, pending more clarity on the financing of the pivotal trial.
Benzinga · 2d ago
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
NASDAQ · 2d ago
Agenus downgraded at Baird after FDA feedback on cancer drug
Healthcare Agenus downgraded at Baird after FDA feedback on cancer drug BOT/BAL. Shares of the biotech fell 5% premarket Friday. The FDA advised against seeking accelerated approval for the colorectal cancer therapy combo, Baird says. The stock fell nearly 60% in the previous session.
Seeking Alpha · 2d ago
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
NASDAQ · 2d ago
BUZZ-Agenus drops after brokerages cut rating; FDA blocks cancer therapy accelerated approval
Agenus Inc shares fall 5.4% to $6.9 in premarket trade after falling as much as 62% in previous session. FDA blocks cancer therapy accelerated approval for colorectal cancer therapy. Brokerages cut ratings on stock to market perform.
Reuters · 2d ago
More
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.